News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
SBP GROUP's Category 1 Innovative Drug M701 NDA Accepted
SBP GROUP (01177.HK) announced that a new drug application (NDA) for M701 “CD3/EpCAM Bispecific Antibody”, a national Category 1 innovative drug jointly developed by Ch...
Reset
Send
The window will close in 5 seconds
SBP GROUP's Category 1 Innovative Drug M701 NDA Accepted
Close
Recommend
21
Positive
29
Negative
7
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

SBP GROUP (01177.HK)  -0.020 (-0.377%)    Short selling $64.38M; Ratio 21.908%   announced that a new drug application (NDA) for M701 “CD3/EpCAM Bispecific Antibody”, a national Category 1 innovative drug jointly developed by Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ), a subsidiary of the Group, for the treatment of malignant ascites (MA) caused by advanced epithelial malignancies, has been submitted to and accepted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration.

M701 is China’s first independently developed CD3/EpCAM bispecific antibody, capable of simultaneously targeting EpCAM on tumor cells and CD3 on immune T cells. By forming a bridge between tumor cells and immune T cells through dual-target binding, it activates T cells to kill tumor cells.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-18 16:25.)

Related NewsG Sachs Raises SBP GROUP (01177.HK) TP to HKD8.05, Maintains Buy on Introduction of GSK Hepatitis B Drug

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.